問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Infectious Disease

China Medical University Hospital-Taipei (在職)

Division of Infectious Disease

更新時間：2023-09-19

王任賢Wang, Jen-Hsien
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

  • jenhsien@mail.cmuh.org.tw

Recruiting Trial

1Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王任賢

List

26Cases

2019-06-14 - 2021-10-19

Phase III

A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed

  • Condition/Disease

    HIV-1 Infections

  • Test Drug

    GSK3515864

Participate Sites
6Sites

Recruiting6Sites

2012-03-31 - 2013-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Study ended5Sites

2012-09-01 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-02-01 - 2015-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Study ended3Sites

2013-11-01 - 2021-12-31

Phase III

Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection

  • Condition/Disease

    C. difficile Infection

  • Test Drug

    C. difficile Toxoid Vaccine

Participate Sites
7Sites

Terminated7Sites

2011-06-01 - 2013-05-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2006-01-01 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2009-09-01 - 2010-09-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2014-02-01 - 2015-11-01

Phase III

A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia

  • Condition/Disease

    Community-Acquired Bacterial Pneumonia

  • Test Drug

    Solithromycin (CEM-101)

Participate Sites
2Sites

Terminated1Sites

Study ended1Sites

2014-09-15 - 2017-04-30

Phase II/III

A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE 3 STUDY TO ASSESS THE SAFETY AND EFFICACY OF INTRAVENOUS CEFTOLOZANE/TAZOBACTAM COMPARED WITH MEROPENEM IN ADULT PATIENTS WITH VENTILATED NOSOCOMIAL PNEUMONIA

  • Condition/Disease

    VENTILATED NOSOCOMIAL PNEUMONIA

  • Test Drug

    Ceftolozane／Tazobactam

Participate Sites
5Sites

Terminated5Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB